sunvozertinib in combination with Anlotinib

DRUG2 trials

Sponsors

Hunan Province Tumor Hospital

Conditions

Non-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 2

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

RecruitingNCT06348927

Hunan Province Tumor HospitalNon-Small Cell Lung Cancer

Start: 2024-07-01End: 2027-04-30Target: 52Updated: 2024-09-19

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

RecruitingNCT06355609

Hunan Province Tumor HospitalNon-small Cell Lung Cancer

Start: 2024-07-01End: 2027-12-30Target: 100Updated: 2024-09-20